Ann Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) said it will commercialize an oral zinc lozenge as a homeopathic over-the-counter treatment for the common cold under the brand name wellZin.
Adeona said it had acquired exclusive access to two sets of clinical data demonstrating, with statistical significance, the safety and efficacy of a particular oral zinc formulation in reducing the duration and severity of symptoms associated with the common cold.READ MORE: Stimulus Check Latest: Will You Get A Fourth Relief Payment?
A randomized, double-blind, placebo-controlled study of 50 participants demonstrated that compared to the placebo group, the zinc lozenge group (13.3 mg of zinc acetate) had a mean overall reduction of the following:
* Duration of the cold (4.0 versus 7.1 days; P-value < 0.0001)
* Cough (2.1 versus 5.0 days; P-value < 0.0001)
* Nasal discharge (3.0 versus 4.5 days; P-value < 0.02)
A randomized, double-blind, placebo-controlled study of 48 participants demonstrated that compared to the placebo group, the zinc lozenge group (12.8 mg of zinc acetate) had a mean overall reduction of the following:
* Duration of the cold (4.5 versus 8.1 days; P-value < 0.01)
* Cough (3.1 versus 6.3 days; P-value < 0.001)
* Nasal discharge (4.1 versus 5.8 days; P-value < 0.025)
The 13.3 mg zinc acetate lozenge is intended to be commercialized. Plans for manufacturing, packaging and marketing of wellZin are currently under way.MORE NEWS: If Kids Are Able To Get COVID Vaccine, Health Department May Re-Evaluate Michigan’s Re-Opening Plan
More at www.adeonapharma.com.